Clinical Study of Factors Associated with Pregnancy Outcomes in Pregnant Women with Systemic Lupus Erythematosus in the Southern China

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2022 Aug 11

PMID 35949873

Authors

Ke Zhang

Chunmei He

Qiaoting Deng

Wengen Li

Zhixiong Zhong

Jingyuan Hou

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to estimate predicted factors for maternal and fetal outcomes in Hakka pregnant women with systemic lupus erythematosus (SLE) in the southern China.

Patients And Methods: Between June 2014 and February 2020, we retrospectively analyzed the data of a total of 123 singleton pregnant women with SLE (mean age: 27.1±4.1 years; range, 19 to 39 years) who were referred to our rheumatology clinic. Demographic, clinical, and laboratory data of the patients were recorded. Adverse pregnancy outcomes (APOs) were assessed.

Results: Multivariate logistic regression analysis revealed that preeclampsia was associated with the increased odds of APOs (odds ratios [OR]=9.538, 95% confidence interval [CI]: 2.055-44.271, p=0.004), premature birth (OR=14.289, 95% CI: 3.596-56.777, p<0.001) and low birth weight (OR=8.275, 95% CI: 2.117-32.345, p=0.002). Anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody positivity was the predictor of APOs (OR=2.165, 95% CI: 1.034-4.532, p=0.040), premature birth (OR=2.849, 95% CI: 1.220-6.657, p=0.016) and pregnancy loss (OR=3.004, 95% CI: 1.086-8.305, p=0.034). The use of hydroxychloroquine and prednisone was associated with the decreased odds of APOs (OR=0.412, 95% CI: 0.198-0.860, p=0.018) and pregnancy loss (OR=0.304, 95% CI: 0.111-0.831, p=0.020).

Conclusion: Our study results indicate that preeclampsia, anti-dsDNA antibody positivity, and the use of hydroxychloroquine and prednisone are independent predictors of pregnancy outcomes.

References

Ramires de Jesus G, Mendoza-Pinto C, de Jesus N, Dos Santos F, Klumb E, Garcia Carrasco M . Understanding and Managing Pregnancy in Patients with Lupus. Autoimmune Dis. 2015; 2015:943490. PMC: 4515284. DOI: 10.1155/2015/943490. View

Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S . Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019; 28(12):1407-1416. DOI: 10.1177/0961203319877258. View

de Jesus G, Rodrigues B, Lacerda M, Dos Santos F, de Jesus N, Klumb E . Gestational outcomes in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2017; 26(5):537-542. DOI: 10.1177/0961203317693929. View

Ling N, Lawson E, von Scheven E . Adverse pregnancy outcomes in adolescents and young women with systemic lupus erythematosus: a national estimate. Pediatr Rheumatol Online J. 2018; 16(1):26. PMC: 5902884. DOI: 10.1186/s12969-018-0242-0. View

Tedeschi S, Bermas B, Costenbader K . Sexual disparities in the incidence and course of SLE and RA. Clin Immunol. 2013; 149(2):211-8. DOI: 10.1016/j.clim.2013.03.003. View

Ko H, Ahn H, Jang D, Choi S, Park Y, Park I . Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci. 2011; 8(7):577-83. PMC: 3198253. DOI: 10.7150/ijms.8.577. View

Lin P, Rhew E, Ness R, Peaceman A, Dyer A, McPherson D . Adverse pregnancy outcomes and subsequent risk of cardiovascular disease in women with systemic lupus erythematosus. Lupus Sci Med. 2014; 1(1):e000024. PMC: 4213826. DOI: 10.1136/lupus-2014-000024. View

Clowse M, Magder L, Petri M . The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol. 2011; 38(6):1012-6. DOI: 10.3899/jrheum.100746. View

Andreoli L, Bertsias G, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N . EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2016; 76(3):476-485. PMC: 5446003. DOI: 10.1136/annrheumdis-2016-209770. View

10.

Hiramatsu Y, Yoshida S, Kotani T, Nakamura E, Kimura Y, Fujita D . Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus. Lupus. 2018; 27(14):2245-2252. DOI: 10.1177/0961203318809178. View

11.

Rees F, Doherty M, Grainge M, Lanyon P, Zhang W . The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017; 56(11):1945-1961. DOI: 10.1093/rheumatology/kex260. View

12.

Saavedra M, Sanchez A, Morales S, Angeles U, Jara L . Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol. 2015; 34(7):1211-6. DOI: 10.1007/s10067-015-2987-x. View

13.

Sciascia S, Hunt B, Talavera-Garcia E, Lliso G, Khamashta M, Cuadrado M . The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2015; 214(2):273.e1-273.e8. DOI: 10.1016/j.ajog.2015.09.078. View

14.

Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M . Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun. 2016; 74:194-200. DOI: 10.1016/j.jaut.2016.06.012. View

15.

Skorpen C, Lydersen S, Gilboe I, Skomsvoll J, Salvesen K, Palm O . Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis. 2017; 77(2):264-269. DOI: 10.1136/annrheumdis-2017-211641. View

16.

Manzano-Gamero V, Pardo-Cabello A, Vargas-Hitos J, Zamora-Pasadas M, Navarrete-Navarrete N, Sabio J . Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study. Int J Rheum Dis. 2017; 21(11):2028-2035. DOI: 10.1111/1756-185X.13117. View

17.

Tincani A, Nalli C, Khizroeva J, Bitsadze V, Lojacono A, Andreoli L . Autoimmune diseases and pregnancy. Best Pract Res Clin Endocrinol Metab. 2019; 33(6):101322. DOI: 10.1016/j.beem.2019.101322. View

18.

Stojan G, Baer A . Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol. 2012; 8(5):439-53. DOI: 10.1586/eci.12.36. View

19.

Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A . Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004; 18(1):93-101. DOI: 10.1016/j.reprotox.2003.10.007. View

20.

Clowse M, Magder L, Witter F, Petri M . Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006; 54(11):3640-7. DOI: 10.1002/art.22159. View